Methods: A total of 90 patients, who had undergone TAVI, were retrospectively studied. Vascular complications were defined as major and minor according to the Valve Academic Research Consortium (VARC) criteria. Patients were divided into High Cannulation Site (CS) group and Low CS group depending on the common femoral artery puncture site position, in regards to the most inferior border of the inferior epigastric artery. Results: Vascular complications were significantly more frequent in the high CS group versus the low CS group (32.3% vs 11.9%, pϭ0.039). High cannulation remained an independent predictor of vascular complications after adjustment for known risk factors (OR: 4.827, CI: 1.441-16.168; pϭ0.011).
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Mortality Risk For Transcatheter Aortic Valve Implementation Patients Eventually Approaches General Population: Innovative Time Series Analysis Of Outcomes
Background: TAVI has increasingly improved outcomes for high-risk patients with severe aortic stenosis. We hypothesize that residual mortality risk eventually approaches that of general population. Methods: 160 patients with severe aortic stenosis who underwent TAVI between January 2007 and October 2011 were assessed. Results: Procedural success rate was 97%. Cumulative survival (& mortality) rates at 1 and 6 months, 1, 2 and 3 years were 91% (9%), 83%(17%), 72% (28%), 65% (35%), and 57% (43%) respectively. However, specific mortality (survival) at the 3rd year for patient group who were alive after 2 yrs post-procedure (30 patients, age range 70-93 yrs; average 82yrs) was 13% (87%), representing the highest whole-year-equivalent-rate of all periods post-procedure. The comparative UK general population annual death risk ranges from 2% at 70yrs to Ͼ17% at 85ϩ yrs. Factors with significant impact on mortality were: At 6 months: COAD (P Ͻ 0.03), extracardiac arteripathy (p Ͻ0.05), poor LV function (pϽ 0.001), previous MI (pϽ0.017), poor LVEF (pϽ0.00117) and high creatinine levels (pϽ0.005); At 1 year: renal disease (p Ͻ0.0001), MI history (p Ͻ0.03); At 2 yrs: poor LVEF (pϽ 0.04), and high creatinine levels (Ͻ0.009); and at 3 yrs: only high creatinine levels (pϽ0.012) with no significance for cardiac factors. Logistic Euroscore had no significant impact at any point. Most deaths occurred before 1 yr, largely by 6 months post procedure (28 deaths-64%); only 4 new deaths occurred in the third year. Conclusions: We presented comparative data at 5 different time points, with outcomes similar or better than other TAVI studies which usually present time-point outcomes separately. Survival for those passing 2 yrs alive is the highest with lowest number of significant mortality linked factors suggesting 'normalisation' towards random (noncardiac) factors in comparative general population. Further analyses is required with larger number of patients for longer time points and this could lead to new paradigm in selection criteria for TAVI patients.
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One Background: Elderly patients with severe aortic stenosis (AS) are high risk for surgical aortic valve replacement (SAVR). Transcatheter aortic valve implantation (TAVI) has emerged as an alternative. The study aim was to compare clinical outcomes of TAVI vs. SAVR in elderly patients with severe AS. Methods: All consecutive patients with severe AS Ն75 years old treated in our center with either TAVI (nϭ226) or SAVR (nϭ222) were analyzed. A propensity score analysis was performed to adjust for differences in baseline clinical characteristics between the two groups. Results: Patients treated with TAVI were significantly older (82.4Ϯ4.3 vs. 79.0Ϯ2.9 years; pϽ0.001) with more co-morbidities, higher Logistic EuroSCORE (25.1Ϯ16.6% vs. 13.1Ϯ11.7%; pϽ0.001) and STS score (8.6Ϯ7.5 vs. 5.8Ϯ7.3; pϽ0.001). At one-year, at the adjusted analysis, there was an advantage favoring TAVI in the primary study objective of VARC combined efficacy endpoint (adjusted odds ratio [OR] 0.45; 95% confidence interval [CI] 0.24-0.86; pϭ0.02). There was no difference in 30-day all-cause mortality at the unadjusted analysis (unadjusted OR 0.98; 95% CI 0.38-2.51; pϭ0.961), however a benefit of TAVI was observed at the adjusted analysis (adjusted OR 0.27; 95% CI 0.08-0.95; pϭ0.041). This was no longer apparent at one-year (adjusted OR 0.78; 95% CI 0.40-1.50; pϭ0.45). Conversely, SAVR had more device success (adjusted OR 0.20; 95% CI 0.06-0.67; pϭ0.01) and less combined safety endpoint (adjusted OR 1.66; 95% CI 1.02-2.69; pϭ0.04) at 30-days.
Conclusions:
In patients Ն75 years with severe AS, at one-year there was similar efficacy between TAVI and SAVR at unadjusted analysis but an advantage of TAVI at adjusted analysis. These results need to be confirmed in a randomized trial. Background: Embolic particles originating at the aortic valve or ascending aorta can have devastating consequences if they enter the cerebral circulation. Little is known about anatomic embolic origin and cerebral events, as this relationship is difficult to observe. To better understand emboli arising from procedures such as TAVR, we built a computational fluid dynamic (CFD) model of cerebral emboli originating at the aortic valve and ascending aorta. Methods: An exact computer model of a human aorta and arteries to the brain was derived from CT angiography. Blood flow was modeled by the Navier-Stokes equations using pulsatile inflow at the inlet and physiologic Windkessel models at the outlets. Embolic particulate was injected at the level of the aortic valve and tracked using modified Maxey-Riley equations. Results: Aortic emboli that entered the cerebral circulation through the carotid or vertebral arteries were localized to specific locations of the proximal aorta, most closely in the region of the right and non-coronary aortic valve cusps. The percent of released particles embolic to the brain was markedly dependent on particle size. Particles 1.0 mm diameter had a 28% chance of reaching the brain, whereas particles 2.5 mm dia or greater had 5% chance of reaching the brain. Conclusions: Embolic particles reaching the brain appear have specific anatomic locations of origin, and may exhibit a strong size-destination relationship, with larger particulate (greater than 2.5 mm dia) less likely to traverse the cerebral vessel by a factor of 5 or greater. Particles less than 2 mm dia and originating from the right and noncoronary cusps appear more likely to cause cerebral injury according to this model. These data are consistent with sparse literature based on transesophageal echo observations. This CFD modeling method may prove useful for limiting aortic emboli to the brain during cardiovascular procedures. 
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